广东丸美生物技术股份有限公司 章 程 二〇二三年八月 | 第一章 | 总则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 4 | | 第一节 | 股份发行 4 | | 第二节 | 股份增减和回购 5 | | 第三节 | 股份转让 7 | | 第四章 | 股东和股东大会 8 | | 第一节 | 股东 8 | | 第二节 | 股东大会的一般规定 10 | | 第三节 | 股东大会的召集 15 | | 第四节 | 股东大会的提案与通知 17 | | 第五节 | 股东大会的召开 19 | | 第六节 | 股东大会的表决和决议 22 | | 第五章 | 董事会 26 | | 第一节 | 董事 26 | | 第二节 | 董事会 29 | | 第六章 | 总经理及其他高级管理人员 35 | | 第七章 | 监事会 36 | | 第一节 | 监事 36 | | 第二节 | 监事会 37 | | 第八章 | 财务会计制度、利润分配和审计 39 | | 第一节 | 财务会计制度 39 | | 第二节 | 内部审计 43 | | 第三节 | 会计师事务所的聘任 43 | | 第九 ...

证券代码：603983 证券简称：丸美股份 公告编号：2023-028 广东丸美生物技术股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广东丸美生物技术股份有限公司（以下简称"公司"或"丸美股份"）于 2023 年 8 月 24 日召开了第四届董事会第十三次会议，审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，拟使用不超过人民币 40,000 万元的闲置募集资金进行现金管 理，该额度可滚动使用，自公司第四届董事会第十三次会议审议通过之日起十二个月内 有效，并提请授权管理层行使决策权并签署相关合同文件，具体事项由公司财务部负责 组织实施。 1、现金管理额度：公司拟使用不超过人民币 40,000 万元暂时闲置的募集资金进行 现金管理，在该额度及本决议有效期内，该 40,000 万元额度可滚动使用。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次公开发 行股票的批复》（证监许可[2019]917 号）核准，并经上海证 ...

经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次 公开发行股票的批复》（证监许可[2019]917 号）核准，并经上海证券交易所同意， 丸美股份首次公开发行人民币普通股（A 股）股票 4,100 万股，发行价格为每股 人民币 20.54 元。共计募集资金人民币 84,214.00 万元，扣除各项发行费用人民 币 5,213.80 万元后的募集资金净额为人民币 79,000.20 万元。上述募集资金到位 情况已经广东正中珠江会计师事务所（特殊普通合伙）审验，并于 2019 年 7 月 22 日出具了广会验字[2019]G16044670870 号《验资报告》。上述募集资金存放于 募集资金专项账户，实行专户管理。 （二）募集资金投资项目使用情况 截至 2023 年 6 月 30 日，公司已累计使用募集资金 34,625.18 万元，尚未使 用的募集资金余额为 44,375.02 万元（不含现金管理专户金额、理财收益和利息 收入），具体情况详见公司同日于上海证券交易所网站披露的《关于 2023 年半年 度募集资金存放与使用情况的专项报告》（公告编号：2023-027）。 中信证券股份有限公司 关于 ...

Financial Performance - Basic earnings per share (EPS) for Q1 2023 was CNY 0.20, representing a 25% increase year-over-year[7] - Total operating revenue for Q1 2023 reached RMB 476,746,492.76, representing a year-on-year increase of 24.58%[25] - Net profit attributable to shareholders of the listed company was RMB 78,669,809.57, up by 20.15% compared to the same period last year[25] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 74,068,664.48, reflecting a growth of 29.03% year-on-year[25] - The net profit for the current period is 78,875,208.55, an increase from 64,155,842.52 in the previous period, representing a growth of approximately 22.5%[48] - The operating profit for the current period is 96,639,099.37, up from 79,251,500.44, marking an increase of around 22%[48] - The company reported a total profit of 96,217,789.11, compared to 79,253,194.59 in the previous period, which is an increase of approximately 21.4%[48] Assets and Liabilities - Total assets increased by 1.62% to CNY 4,157,516,295.59 compared to the end of the previous year[7] - Net assets attributable to shareholders increased by 2.47% to CNY 3,266,745,172.79 from the end of the previous year[7] - The total current assets amounted to CNY 2,272,875,458.65, showing an increase from CNY 2,237,236,911.48[37] - The total non-current assets reached CNY 1,884,640,836.94, compared to CNY 1,853,986,684.20 in the previous period[37] - The total current liabilities were CNY 805,052,496.20, up from CNY 668,472,002.53[38] - The company’s total liabilities amounted to CNY 826,214,377.68, a slight decrease from CNY 838,639,456.55[38] - The total liabilities and equity reached 4,157,516,295.59, compared to 4,091,223,595.68 in the previous period, indicating an increase of approximately 1.6%[46] Cash Flow - Cash received from operating activities increased by 41.08% compared to the same period last year[9] - The net cash flow from operating activities was negative at RMB -45,715,441.84, indicating a cash outflow[25] - The net cash flow from operating activities was negative at CNY -45,715,441.84, an improvement from CNY -66,727,953.44[43] - Cash inflow from investment activities was CNY 185,603,869.84, while cash outflow was CNY 191,989,461.89, resulting in a net cash flow of CNY -6,385,592.05[43] - Cash inflow from financing activities was CNY 100,000,000.00, with a net cash flow of CNY 95,462,171.83[43] - The cash and cash equivalents at the end of the period amounted to 1,105,303,010.46, up from 650,418,991.12, representing a significant increase of about 69.8%[51] - The cash and cash equivalents stood at RMB 1,117,907,244.39 as of March 31, 2023, compared to RMB 1,073,008,990.19 at the end of 2022[35] - The cash and cash equivalents increased by CNY 43,322,637.76, contrasting with a decrease of CNY -163,096,789.85 in the previous period[43] Expenses - Total operating costs for Q1 2023 amounted to RMB 387,469,124.96, an increase from RMB 310,654,952.39 in Q1 2022[25] - Sales expenses increased by 41.28% year-over-year, reflecting higher marketing costs[8] - Research and development expenses were RMB 13,356,993.07, slightly higher than RMB 13,193,134.18 in the previous year[25] - Prepayments surged by 249.29% primarily due to increased marketing expenses[8] - Short-term borrowings rose by 100.07%, indicating a significant increase in short-term debt[8] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,605[9] - The total equity attributable to shareholders of the parent company increased to 3,266,745,172.79 from 3,188,071,719.97, reflecting a growth of about 2.5%[46] - The unallocated profits increased to 1,905,869,534.54 from 1,827,181,623.62, showing a growth of approximately 4.3%[46] - The minority shareholders' profit increased to 205,398.98 from a loss of 1,320,242.77, indicating a positive turnaround[48] Other Income - Interest income grew by 46.32% due to increased interest from time deposits[8] - The company reported investment income of RMB 7,882,869.87, up from RMB 7,185,543.38 in Q1 2022[17] - Comprehensive income for the period totaled RMB 78,860,750.45, compared to RMB 63,946,761.01 in the same quarter last year[19] - The company recorded a credit impairment loss of 638,831.24, compared to a recovery of 179,123.18 in the previous period, indicating a negative shift in credit quality[48] - The company’s other comprehensive income attributable to the parent company decreased to -14,458.10 from -209,081.51, showing an improvement in this area[48]

Financial Performance - The company reported a total revenue of 124,424.36 million RMB from online sales, representing a year-over-year increase of 21.06%[6] - Offline sales revenue was 48,557.38 million RMB, showing a decline of 30.49% compared to the previous year[6] - The company reported a decrease in net profit and earnings per share due to a decline in sales revenue compared to the previous year, alongside increased expenses from expanding online channels[48] - The company reported a net profit of 562.67 million RMB from its subsidiary, Marumi Technology, while other subsidiaries reported losses[3] - The company’s net profit attributable to shareholders was 174 million RMB, a decline of 29.74% year-on-year, primarily due to increased expenses from the online channel transformation[103] - The company achieved a significant breakthrough in online e-commerce operations in Q4 2022, enhancing its competitive advantage and laying a solid foundation for long-term high-quality development[55] - The company reported a total pre-tax remuneration of 183.38 million CNY for the CEO during the reporting period[175] - The company reported a revenue increase of 15% year-over-year, reaching 1.2 billion RMB in the last quarter[181] - The company’s overall sales expenses increased by 14.15% year-on-year to 846 million RMB, while management expenses rose by 10.87% to 111 million RMB[103] Gross Profit and Margins - The gross profit margin for the eye care segment increased by 6.46 percentage points to 68.74%, despite a revenue decrease of 16.73%[6] - The skincare segment's gross profit margin improved by 2.44 percentage points to 68.13%, with a revenue decline of 17.80%[6] - The company's gross margin increased to 68.40%, up 4.38 percentage points, due to optimized sales strategies and cost control, leading to higher prices for regular products and a reduction in promotional items[103] - The gross profit margin improved by 4.31 percentage points to 68.45% due to a decrease in operating costs by 11.85% to ¥545,763,947.39[137] - The gross margin improved to 45%, up from 40% in the previous year, indicating better cost management[181] Investments and Assets - The company has invested 99.90% in the Qingdao Maoda Equity Investment Partnership, increasing its total investment to 9,990 million RMB[11] - The total assets of the company’s major subsidiaries include 109,476.89 million RMB for Chongqing Bodo and 49,553.04 million RMB for Marumi Technology[3] - The company's total assets increased by 8.76% year-over-year, reaching approximately ¥4.09 billion[70] Production and Capacity - The company has established a new production base in Guangzhou with a design capacity of 1,710 tons for cosmetics, which officially commenced production in 2022[16] - The intelligent manufacturing factory in Guangzhou is expected to add 3,382.50 tons of skincare product capacity, with completion anticipated in 2023[16] - The company is currently evaluating the construction progress and future arrangements for its intelligent manufacturing project due to external uncertainties[16] Research and Development - The company applied for 77 new patents and received 69 new authorizations during the reporting period, including 55 invention patents[80] - R&D expenses amounted to 52.93 million RMB, reflecting a year-on-year increase of 4.83%, indicating continued investment in innovation[103] - The number of R&D personnel is 93, accounting for 8.77% of the total workforce[2] - The company is investing 50 million RMB in R&D for new technologies aimed at enhancing product efficiency[181] Procurement and Operating Costs - The procurement of additives showed a price decrease of 2%, while liquid oils, emulsifiers, and surfactants experienced price increases of 15%, 11%, and 15% respectively, impacting overall operating costs[19] - The average procurement price for water increased by 6%, electricity by 16%, and gas by 14%, contributing to higher operating costs[20] - The company has implemented phase-based reserves for long-cycle imported raw materials to mitigate risks associated with price fluctuations[23] - The company reduced its procurement costs, with raw material costs decreasing by 15.52% to ¥344,214,966.74[140] - Operating costs decreased by 14.89% to approximately 547.29 million RMB compared to the previous period[136] Market and Sales Strategy - The main brand "MARUBI" has established itself as a leading brand in the domestic high-end cosmetics market, recognized for its eye care products and anti-aging category[29] - The online channel generated 1.24 billion RMB in revenue, representing 71.93% of total revenue, with a year-on-year growth of 21.06%, primarily driven by the rapid development of Douyin and Kuaishou self-broadcasting and the Lianhuo brand[110] - The Lianhuo brand achieved revenue of 286 million RMB, a significant increase of 331.91% year-on-year, contributing 16.52% to total revenue[103] - The company optimized its product structure by reducing over 200 SKUs and focused on different sales strategies for online and offline channels[83] - The revenue from the restructured double collagen protein series reached approximately ¥205 million, accounting for 11.84% of the company's total revenue[83] Digital Transformation and Technology - The company completed its digital transformation 1.0 in 2022, establishing a comprehensive digital middle platform and integrating 12 internal systems with 46 external data sources[113] - The company initiated a three-year digital transformation 2.0 plan to enhance the application of data assets for high-quality development[113] - The company maintained a strong focus on digital transformation, improving supply chain efficiency and reducing inventory to historical lows, achieving a 45-day delivery time for key products[88] - The company plans to enhance its digital marketing strategy, allocating an additional 30 million RMB for online campaigns[181] Governance and Management - The company has established a comprehensive board governance structure with 9 directors, including 3 independent directors, ensuring effective decision-making[170] - The company has not experienced any significant governance issues or interference from major shareholders during the reporting period[172] - The independent director Qin Xin resigned due to personal work reasons, and the board has nominated Mr. Cao Yong as a candidate for independent director[199] - The company held one annual and one extraordinary shareholders' meeting during the reporting period, adhering to legal and procedural requirements[189] - The company is committed to continuous improvement in operational standards and governance practices to ensure long-term stability and growth[188] Future Outlook and Strategic Goals - The company plans to focus on "user-centric, excellent products, refined market operations, and precise management" in 2023[155] - The company aims for a comprehensive recovery and healthy growth in 2023, emphasizing execution and conversion[155] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[181] - Market expansion plans include entering three new regions, projected to increase market share by 5%[181] - The company aims for multi-brand and multi-channel collaborative development, prioritizing user-centric fine operations and continuous R&D innovation[168]

证券代码：603983 证券简称：丸美股份 公告编号：2023-020 广东丸美生物技术股份有限公司 关于召开2022年度暨2023年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023年05月18日(星期四) 下午 13:00-14:30 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络文字互动 投资者可于2023年05月11日(星期四) 至05月17日(星期三)16:00前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮箱 securities@marubi.cn进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 广东丸美生物技术股份有限公司（本文简称"公司"）已于 2023 年 4 月 29 日在 上海证券交易所网站（www.sse.com.cn）分别披露了公司 2022 年年度报告、2023 年第一季度报告。为便于广大投 ...

2022 年第三季度报告 单位：元币种：人民币 证券代码：603983 证券简称：丸美股份 广东丸美生物技术股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|------------------------------|------------------|------------------------------ ...

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥817.18 million, a decrease of 6.48% compared to ¥873.80 million in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥117.07 million, down 38.11% from ¥189.15 million in the previous year[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥100.85 million, a decrease of 36.57% compared to ¥158.98 million in the same period last year[21]. - Basic earnings per share for the first half of 2022 were ¥0.29, down 38.30% from ¥0.47 in the same period last year[21]. - The company achieved a revenue of 817 million, a year-on-year decrease of 6.48%, with an overall gross margin of 69.21%, an increase of 5.14 percentage points[34]. - The net profit attributable to shareholders was 117 million, a year-on-year decrease of 38.11%, while the net profit after deducting non-recurring gains and losses was 101 million, down 36.57%[34]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a 25% year-over-year growth[100]. - The company reported a total comprehensive income of CNY -76.3 million for the period[177]. - The total equity at the end of the period reached 2,533,911,145.91 RMB, with a notable increase in retained earnings of 1,168,181,531.45 RMB[193]. Cash Flow and Assets - The net cash flow from operating activities increased to approximately ¥13.08 million, compared to a negative cash flow of ¥42.51 million in the same period last year[21]. - Cash and cash equivalents increased by 22.16% to approximately 984.76 million, accounting for 25.78% of total assets[51]. - Inventory decreased by 10.77% to approximately 123.51 million, representing 3.23% of total assets[51]. - The company reported a significant increase of 47.85% in construction in progress, totaling approximately 175.37 million, due to new factory and office building projects[51]. - The total assets at the end of the reporting period were approximately ¥3.82 billion, an increase of 1.56% from ¥3.76 billion at the end of the previous year[21]. - The company reported cash outflow from investment activities of CNY 482,600,879.00, a decrease from CNY 1,262,649,817.16 in the previous year[164]. - The total liabilities reached ¥624,588,101.25, an increase from ¥603,185,131.96, which is a growth of around 3.67%[141]. Research and Development - Research and development expenses amounted to 24.64 million, maintaining a consistent investment level[34]. - The company focuses on technological innovation, advancing research in gene engineering, biological fermentation, and plant extraction[37]. - The company has expanded its partnerships with three universities for research projects, enhancing its R&D capabilities[37]. - The company applied for 34 new patents, including 31 invention patents and 3 utility model patents, and received 39 new patent authorizations, including 35 invention patents[40]. - The company is investing 200 million yuan in research and development for new technologies aimed at enhancing product efficiency[104]. Market and Competition - The cosmetics industry faced challenges, with retail sales of cosmetics declining by 2.5% in the first half of 2022[28]. - The company faced intensified market competition in the cosmetics industry, necessitating continuous product innovation and brand building[58]. - The company is actively adjusting its product structure and implementing cost control measures to mitigate the impact of rising raw material and labor costs[36]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for potential deals[106]. Corporate Governance and Compliance - The company reported no profit distribution plan or capital reserve transfer plan for the reporting period[6]. - The company completed the repurchase and cancellation of restricted stock on July 7, 2022, as part of its stock incentive plan[67]. - The company committed to not transferring benefits to other entities or individuals without fair conditions, ensuring the protection of investor interests[95]. - The company will ensure that any share reduction complies with the Shanghai Stock Exchange rules and relevant laws[80]. - The company emphasizes the importance of maintaining compliance with legal and regulatory requirements in its stock repurchase and stabilization efforts[88]. Strategic Initiatives - The company is focusing on optimizing supply chain processes and reducing costs to improve efficiency, which contributed to the positive cash flow from operating activities[21]. - The company has established a complete supply chain system for raw material procurement, sourcing from international manufacturers such as BASF and Dow[30]. - The company has established partnerships with multiple universities and research institutions, leading to the initiation of key R&D projects in green bio-manufacturing[38]. - The company is enhancing its digital capabilities by integrating data across various online platforms, improving decision-making for new product development and marketing strategies[44]. Shareholder Information - The company’s major shareholders have committed to not transferring shares for 36 months post-IPO and have outlined specific conditions for any future share reductions[77]. - The company holds 15% of its shares, with a reduction period of six months from the announcement of the reduction plan[80]. - The company will implement stock buyback measures if the stock price stabilization conditions are triggered, with a maximum of 20% of the previous year's net profit allocated for buybacks[82]. - The company will not transfer shares for six months following any violation of share reduction commitments[80].

Financial Performance - The company's operating revenue for 2021 was RMB 1,787,028,564.22, representing a year-on-year increase of 2.41% compared to RMB 1,744,989,060.09 in 2020[23]. - Net profit attributable to shareholders decreased by 46.61% to RMB 247,921,313.25 in 2021 from RMB 464,399,184.10 in 2020[25]. - The basic earnings per share (EPS) fell by 46.55% to RMB 0.62 in 2021, down from RMB 1.16 in 2020[25]. - The net cash flow from operating activities showed a significant decline of 102.06%, resulting in a negative cash flow of RMB -7,480,531.05 in 2021 compared to RMB 362,345,691.31 in 2020[25]. - The company's total assets decreased by 0.88% to RMB 3,761,645,909.30 at the end of 2021, down from RMB 3,795,081,810.34 at the end of 2020[23]. - The weighted average return on equity (ROE) dropped by 8.37 percentage points to 8.15% in 2021 from 16.52% in 2020[25]. - The company reported a net profit of RMB 100,127,604.69 in Q1 2021, with a notable decline in Q3 showing a loss of RMB -47,145,694.92[29]. - Non-recurring gains and losses totaled RMB 68,966,817.35 in 2021, compared to RMB 60,483,002.98 in 2020[31]. Dividend Policy - The company plans to distribute a cash dividend of 1.90 RMB per 10 shares (including tax) to all shareholders registered on the dividend distribution date[7]. - The company aims to enhance employee benefits by adjusting salary levels based on local market conditions and company performance[162]. - The company’s profit distribution policy emphasizes sustainable development while ensuring reasonable returns to investors[166]. - The company plans to prioritize cash dividends in profit distribution, with a cumulative distribution of at least 30% of the average annual distributable profits over the last three years[167]. Research and Development - The company invested 50.49 million yuan in R&D, reflecting a commitment to innovation and product quality[38]. - A total of 104 new patents were applied for, including 90 invention patents, demonstrating the company's focus on research and development[43]. - The company is focusing on expanding its production capabilities and enhancing its research and development in bioactive materials for applications in cosmetics and future medical devices[102]. - The number of R&D personnel was 97, making up 8.10% of the total workforce[79]. Marketing and Sales - The company achieved online revenue of 1.028 billion yuan, accounting for 59.54% of total revenue, with a year-on-year growth of 8.17%[51]. - The company’s digital initiatives improved member registration rates from 75% to 93%, enhancing user engagement and operational efficiency[48]. - The company covered over 80 cities with elevator advertising, achieving an exposure of 19.8 billion people, and cinema advertising reached 130 million exposures[49]. - The company conducted approximately 1,800 member salon meetings, covering nearly 50,000 members, and over 7,000 new product experience meetings, reaching around 60,000 members[51]. Governance and Compliance - The company has received a standard unqualified audit report from Huaxing Accounting Firm[6]. - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations, and maintaining independence from its controlling shareholders[129]. - The board of directors has held 8 meetings with 100% attendance, demonstrating commitment to effective governance and decision-making[133]. - The company has a structured decision-making process for determining the remuneration of directors and senior management, involving the remuneration and assessment committee[148]. Operational Efficiency - The company upgraded its channel management system and cloud warehouse, enhancing management efficiency and providing real-time data visualization for supply chain processes[52]. - The company has implemented strict production process controls in accordance with GMPC and ISO standards to ensure product safety and effectiveness[99]. - The company has a green manufacturing initiative, having been recognized as a "Green Factory" in Guangzhou, promoting energy efficiency and resource recycling[183]. - The company has established a green factory committee to oversee environmental management and ensure compliance with eco-friendly practices[183]. Market Position and Strategy - The company’s main brand "MARUBI" is recognized as a leading brand in the domestic cosmetics market, particularly in the anti-aging category[93]. - The company continues to rely on a distribution model that leverages distributors' networks to enhance market penetration, while managing risks associated with distributor performance[122]. - The cosmetics industry is undergoing channel structural changes, prompting the company to strengthen existing advantages while exploring new channels[123]. - The company adheres to a "long-termism strategy" focusing on "technology-driven beauty and health," with four strategic pillars: user-centricity, excellent products, market precision, and refined operations[117].

2022 年第一季度报告 单位：元币种：人民币 证券代码：603983 证券简称：丸美股份 广东丸美生物技术股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |----------------------------------|----------------|------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 | | | | 变动幅度 (%) | | 营业收入 | 382,674,453.43 | -5.31 | | 归属于上市公 ...